The dopamine–somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways-Reference-Cited by-同舟云学术

The dopamine–somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways

Published:2010-02 Issue:2 Volume:288 Page:170-176
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Peverelli Erika,Olgiati Luca,Locatelli Marco,Magni Paolo,Fustini Marco Faustini,Frank Giorgio,Mantovani Giovanna,Beck-Peccoz Paolo,Spada Anna,Lania Andrea

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence;Losa;J. Neurosurg.,2008

2. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors;Ferrante;Eur. J. Endocrinol.,2006

3. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth;Greenman;Clin. Endocrinol.,2003

4. Expression analysis of dopamine receptor subtypes in normal human pituitaries, non-functioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly;Neto;J. Clin. Endocrinol. Metab.,2009

5. Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically non-functioning pituitary adenomas;Renner;J. Clin. Endocrinol. Metab.,1998

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells;International Journal of Molecular Sciences;2024-03-23

2. The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas—New Potential Therapeutic Approach—A Systematic Review;International Journal of Molecular Sciences;2023-06-30

3. Current medical treatment and perspective in gonadotroph tumors;Best Practice & Research Clinical Endocrinology & Metabolism;2022-12

4. DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells;Frontiers in Endocrinology;2022-06-03

5. The dopaminergic control of Cushing’s syndrome;Journal of Endocrinological Investigation;2022-04-23